BIOMAT Database Logo BIOMAT Database Logo

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. 1995

E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595, USA.

The immunogenicity and toxicity of a purified influenza virus (N2) neuraminidase vaccine (NAV) were investigated in 88 human subjects aged 18-40, and compared to response to a conventional trivalent influenza vaccine, Fluogen (Parke-Davis). NAV doses ranged from 2.6 to 69.9 micrograms and were given intramuscularly. Serologic neuraminidase-inhibiting (NI) and neuraminidase-specific ELISA responses in this N2-primed population were roughly proportional to the dose administered. Maximal response was seen in 14-21 days and NI antibody titers persisted unabated for the 6-month post-vaccination follow-up period. All doses were well tolerated with respect to local and systemic reactions. NI tests performed with the putative (1975) priming N2 antigen demonstrated anamnestic response but did not reveal responses not already shown with the homologous (1992) antigen. Response to this purified, non-adjuvanted preparation encourages continuing investigation of the induction of infection-permissive immunity with influenza virus neuraminidase.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D002846 Chromatography, Affinity A chromatographic technique that utilizes the ability of biological molecules, often ANTIBODIES, to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Bioaffinity,Immunochromatography,Affinity Chromatography,Bioaffinity Chromatography
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody

Related Publications

E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Preparation and characterization of a purified influenza virus neuraminidase vaccine.
December 1995, Vaccine,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Epidermal DNA vaccine for influenza is immunogenic in humans.
May 2006, Vaccine,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine.
June 1976, Postgraduate medical journal,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Purified viral neuraminidase vaccine to control influenza.
December 1979, Canadian Medical Association journal,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.
April 1977, The Journal of infectious diseases,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Electron microscopy of purified influenza virus neuraminidase.
December 1968, Virology,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.
July 2016, Vaccine,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
Preliminary crystallographic analysis of neuraminidase N2 from a new influenza A virus.
August 2013, Acta crystallographica. Section F, Structural biology and crystallization communications,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
[Radioimmunological analysis of the neuraminidase of influenza virus subtype N2].
January 1983, Voprosy virusologii,
E D Kilbourne, and R B Couch, and J A Kasel, and W A Keitel, and T R Cate, and J H Quarles, and B Grajower, and B A Pokorny, and B E Johansson
A highly immunogenic vaccine against A/H7N9 influenza virus.
February 2016, Vaccine,
Copied contents to your clipboard!